Bluebird bio Inc

BLUE

NASDAQ. Currency in USD

7.18 -0.52 ( -6.75% )

Real time prices: December 19

Market Cap.
595.29M
Beta (5Y monthly)
1.02
Price/Earnings
-
EPS (TTM)
-5.69
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
4.27M
1y Target Est.
7.33
Day's Range
6.73
-
7.79
52 Week's Range
2.87
-
8.58

Historical Summary

Performance
EPS growth
Share Buybacks

About Bluebird bio Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.bluebirdbio.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
70.11M
Employees
518
Address
60 Binney Street, Cambridge, MA, United States, 02142
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Latest news

bluebird (BLUE) Up on Positive Data on Gene Therapies at ASH
bluebird (BLUE) Up on Positive Data on Gene Therapies at ASH

bluebird (BLUE) gains on positive data on Zyntgelo in beta-thalassemia and lovo-cel in sickle cell...
By Zacks Investment Research - 7 weeks ago

Why Bluebird Bio Stock Crushed the Market Today
Why Bluebird Bio Stock Crushed the Market Today

The company looks set to continue its good momentum in the early part of next...
By The Motley Fool - 7 weeks ago

Why Is Bluebird (BLUE) Up 6.2% Since Last Earnings Report?
Why Is Bluebird (BLUE) Up 6.2% Since Last Earnings Report?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 8 weeks ago

2 Risky Stocks That Could Soar in 2023
2 Risky Stocks That Could Soar in 2023

These "exciting" companies aren't for everyone.
By The Motley Fool - 8 weeks ago

bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale
bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale

bluebird (BLUE) is set to sell one of its two priority review vouchers. This will...
By Zacks Investment Research - 9 weeks ago

bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals
bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel...
By Zacks Investment Research - 10 weeks ago

Where Will Editas Medicine Be in 1 Year?
Where Will Editas Medicine Be in 1 Year?

The company could continue lagging the market for a while.
By The Motley Fool - 11 weeks ago

2 Growth Stocks That Could Double in 2023
2 Growth Stocks That Could Double in 2023

Both are lagging the market this year.
By The Motley Fool - 11 weeks ago